On Thursday, the Senate voted to confirm Stephen Hahn, MD, FASTRO, chief medical executive at the University of Texas MD Anderson Cancer Center, as the 24th commissioner of the FDA.
On Thursday, the Senate voted to confirm Stephen Hahn, MD, FASTRO, chief medical executive at the University of Texas MD Anderson Cancer Center, as the 24th commissioner of the FDA. The final vote was 72 to 18.
Among those voting against confirmation were Senators Kristen Gillibrand, D-New York; Ron Wyden, D-Oregon; and Chuck Schumer, D-New York.
Hahn received a relatively speedy confirmation to lead the agency, having been nominated by President Donald Trump just last month. During the past few weeks, however, little information about has emerged about Hahn’s strategies for leading the FDA, or about his position on fostering the US market for biosimilars.
During the confirmation process, speaking before the Senate Committee on Health, Education, Labor and Pensions, Hahn said that the FDA must encourage innovation and foster competition in order to have access to “a continuously improving universe of treatments,” and pledged to work in a bipartisan manner to serve the public.
He added that Americans want action on the problem of drug pricing, voiced support for generics and biosimilars in general, and indicated that he would work with Congress to address any delays in access to treatments that arise from the upcoming March 2020 transition of insulins to regulation as biologics.
The Biosimilars Forum congratulated Hahn on his confirmation, saying in a statement that it hopes to work with him to “translate urgency into action” on the matter of developing the biosimilars market.
However, given the robust support that biosimilars enjoyed under former commissioner Scott Gottlieb, MD, stakeholders may be left wondering whether Hahn will continue to make the FDA a vocal supporter of biosimilar competition.
During his tenure at the agency, Gottlieb oversaw the release of the Biosimilar Action Plan, called on drug makers to “end the shenanigans” that block biosimilars (including the misuse of Risk Evaluation and Mitigation Strategy programs), and took aim at pay-for-delay tactics as well as rebate and contracting provisions, all of which he said were making the biosimilars market unstable.
Even after Ned Sharpless, MD, took up his post as acting commissioner after Gottlieb’s resignation, biosimilars saw steps forward, with the approval of new biosimilars and the release of the agency’s long-awaited final guidance on interchangeability.
Additionally when Admiral Brett Giroir stepped in to helm the agency between Sharpless’ departure and Hahn’s confirmation, the agency released its momentous draft guidance on clinical immunogenicity considerations for biosimilar insulins and interchangeable insulins.
That guidance, which indicated that interchangeable insulins will not generally require switching studies, represented a substantial shift in the agency’s thinking; some experts told The Center for Biosimilars® that Giror’s brief tenure in the post may have made him an ideal person to try out new ideas that could accelerate biosimilar availability before the arrival of the new commissioner whose views on biosimilars are as yet unclear to stakeholders.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.
Eye on Pharma: Denosumab Biosimilar Data; COA Forms New Committee; IGBA and WHO Collaborate
November 8th 2023Samsung Bioepis releases data for its denosumab biosimilar candidate; the Community Oncology Alliance (COA) forms the Drug Policy and Regulation Committee; the International Generic and Biosimilar Association (IGBA) and the World Health Organization (WHO) collaborate on a new initiative.